News

Clinigen Limited has agreed to acquire Drug Safety Navigator Inc. (‘DSN’), a specialist pharmacovigilance service provider based in the US. This acquisition enables Clinigen to add…
Read More...

Envisagenics, an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with …
Read More...

Neogene Therapeutics, Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies…
Read More...

Glioblastoma multiforme (GBM), the most common type of brain cancer, is notoriously difficult to treat. Its tumor cells mutate rapidly, pushing into deep areas of the brain that can be…
Read More...

Gilead Sciences, Inc. announced that the European Commission (EC) has authorized a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir…
Read More...

ANI Pharmaceuticals, Inc. announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Fluoxetine Oral…
Read More...

C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402 million, for its NRF2 Activator programme.  AstraZeneca will develop…
Read More...

Full-Life Technologies, a fully integrated global radiotherapeutics company, announced an agreement to acquire New Jersey-based Focus-X Therapeutics, a company developing targeted…
Read More...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a…
Read More...

The Global Antibiotic Research and Development Partnership (GARDP) and Mitsubishi Tanabe Pharma Corporation (MTPC) have signed an agreement for GARDP to access over 50,000 compounds…
Read More...

AbbVie announced the European Commission (EC) approved SKYRIZI (risankizumab, 600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) as the first specific…
Read More...

Xeris Biopharma Holdings, Inc. a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of…
Read More...

XtalPi announced that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. XtalPi and CK Life Sciences will leverage their…
Read More...

Sirona Biochem Corp. announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals (“Wanbang”) have signed an expanded, international partnership agreement to collaborate…
Read More...

FUJIFILM Corporation announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The new site will…
Read More...

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for cobas MPXV for use on the cobas 6800/8800 Systems. The test is a real time…
Read More...

IVERIC bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura), a novel…
Read More...

Takeda announced that the randomized, Phase 3 PhALLCON trial met its primary endpoint, demonstrating that adult patients with newly-diagnosed Philadelphia chromosome-positive acute…
Read More...

Alexion, AstraZeneca Rare Disease, announced the completion of its acquisition of LogicBio Therapeutics, Inc. The acquisition creates an opportunity to accelerate Alexion’s growth in…
Read More...